Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 5:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: methylnaltrexone Clear all
Completed Phase 3 Interventional

Open-Label Treatment Extension of Protocol MNTX 301

NCT01367600
View directory record Official record
Conditions
Terminal Illness
Interventions
SC Methylnaltrexone (MNTX)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 28, 2026, 5:54 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation

NCT00804141
View directory record Official record
Conditions
Constipation
Interventions
N-methylnaltrexone bromide (MOA-728)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
94
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Sep 28, 2026, 5:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function

NCT01367561
View directory record Official record
Conditions
Healthy Males
Interventions
Naloxone, IV Methylnaltrexone (MNTX), Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 28, 2026, 5:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function

NCT01367522
View directory record Official record
Conditions
Liver Dysfunction
Interventions
SC Methylnaltrexone (MNTX)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 28, 2026, 5:54 PM EDT
Completed Phase 2 Interventional Results available

Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures

NCT00640146
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Methylnaltrexone bromide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 28, 2026, 5:54 PM EDT
Completed Phase 1 Interventional

Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies

NCT01015222
View directory record Official record
Conditions
Advanced Cancer
Interventions
Dasatinib, Bevacizumab, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Sep 28, 2026, 5:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Pharmacokinetics of Intravenous Administered 14C-MNTX

NCT01367483
View directory record Official record
Conditions
Healthy Male Volunteers
Interventions
IV methylnaltrexone (MNTX)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 28, 2026, 5:54 PM EDT
Completed Phase 3 Interventional

Study of Methylnaltrexone (MNTX) for the Relief of Constipation

NCT00402038
View directory record Official record
Conditions
Advance Illness Patients With OIC
Interventions
SC Methylnaltrexone, SC Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 28, 2026, 5:54 PM EDT
Withdrawn Phase 2Phase 3 Interventional

A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

NCT04083651
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Methylnaltrexone bromide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Sep 28, 2026, 5:54 PM EDT
Completed Phase 3 Interventional

A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients

NCT00401362
View directory record Official record
Conditions
Advanced Illness Patients With Opioid Induced Constipation
Interventions
SC Methylnaltrexone, SC Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 28, 2026, 5:54 PM EDT
Withdrawn No phase listed Observational

RELISTOR's Effects on Opioid-Induced Constipation

NCT04930237
View directory record Official record
Conditions
OIC
Interventions
Relistor Injectable Product, Docusate Calcium, Bisacodyl, Milk of magnesia, Magnesium citrate, Senna, Enema
Drug
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 28, 2026, 5:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan

NCT01367535
View directory record Official record
Conditions
Healthy Adults
Interventions
SC Methylnaltrexone (MNTX), IV Methylnaltrexone (MNTX), Oral Paroxetine, SC Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 28, 2026, 5:54 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain

NCT00529087
View directory record Official record
Conditions
Constipation
Interventions
N-methylnaltrexone bromide (MOA-728), placebo
Drug · Other
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
78
States / cities
Mobile, Alabama • Sun City, Arizona • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 28, 2026, 5:54 PM EDT
Completed Phase 2 Interventional Results available

Methylnaltrexone for Opioid-induced Constipation in Cancer Patients

NCT01004393
View directory record Official record
Conditions
Neoplasms, Constipation, Opioid-Related Disorders
Interventions
Methylnaltrexone bromide
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Sep 28, 2026, 5:54 PM EDT
Completed Phase 3 Interventional

Open-Label Treatment Extension of Protocol MNTX 302

NCT01367613
View directory record Official record
Conditions
Terminal Illness
Interventions
SC Methylnaltrexone
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 28, 2026, 5:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult Subjects

NCT01366326
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
Methylnaltrexone bromide
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 28, 2026, 5:54 PM EDT
Completed Phase 3 Interventional

Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus

NCT00387309
View directory record Official record
Conditions
Post Operative Bowel Dysfunction
Interventions
Methylnaltrexone (MOA-728)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
59
States / cities
Mobile, Alabama • Fort Smith, Arkansas • Chula Vista, California + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 28, 2026, 5:54 PM EDT
Completed Phase 2 Interventional

Intravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative Ileus

NCT01367548
View directory record Official record
Conditions
Postoperative Ileus
Interventions
IV Methylnaltrexone (MNTX), Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 28, 2026, 5:54 PM EDT
Completed Phase 4 Interventional Results available

Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness

NCT00672477
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
Methylnaltrexone, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
29
States / cities
Mobile, Alabama • Laguna Hills, California • Lancaster, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Sep 28, 2026, 5:54 PM EDT
Terminated Phase 4 Interventional Results available

Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids

NCT02977286
View directory record Official record
Conditions
Constipation
Interventions
Naloxegol Oral Tablet, Placebo Oral Tablet, Docusate Sodium 100 Mg oral capsule [Colace], Senna 217 Mg Oral Tablet, Polyethylene Glycols, Bisacodyl 10 mg Suppository, Magnesium Citrate Oral Liquid Product, Methylnaltrexone
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 28, 2026, 5:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets

NCT01366352
View directory record Official record
Conditions
Normal Volunteers
Interventions
MNTX tablet (Formulation 1), MNTX tablet (Formulation 2)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 28, 2026, 5:54 PM EDT